Join
Live feed
·
NEWSReleasevia Quantisnow
AstraZeneca PLC logo
Bristol-Myers Squibb Company logo
Fusion Pharmaceuticals Inc. logo
+2

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments

ByQuantisnow·Wall Street's wire, on your screen.
AZN· AstraZeneca PLCBMY· Bristol-Myers Squibb CompanyFUSN· Fusion Pharmaceuticals Inc.LLY· Eli Lilly and CompanyRYZB· RayzeBio Inc.
Health Care
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments | Quantisnow